326 related articles for article (PubMed ID: 23255114)
1. Stacking the DEK: from chromatin topology to cancer stem cells.
Privette Vinnedge LM; Kappes F; Nassar N; Wells SI
Cell Cycle; 2013 Jan; 12(1):51-66. PubMed ID: 23255114
[TBL] [Abstract][Full Text] [Related]
2. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
3. Melanoma proliferation and chemoresistance controlled by the DEK oncogene.
Khodadoust MS; Verhaegen M; Kappes F; Riveiro-Falkenbach E; Cigudosa JC; Kim DS; Chinnaiyan AM; Markovitz DM; Soengas MS
Cancer Res; 2009 Aug; 69(16):6405-13. PubMed ID: 19679545
[TBL] [Abstract][Full Text] [Related]
4. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
[TBL] [Abstract][Full Text] [Related]
5. High-affinity interaction of poly(ADP-ribose) and the human DEK oncoprotein depends upon chain length.
Fahrer J; Popp O; Malanga M; Beneke S; Markovitz DM; Ferrando-May E; Bürkle A; Kappes F
Biochemistry; 2010 Aug; 49(33):7119-30. PubMed ID: 20669926
[TBL] [Abstract][Full Text] [Related]
6. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
[TBL] [Abstract][Full Text] [Related]
7. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
8. Exosomal DEK removes chemoradiotherapy resistance by triggering quiescence exit of breast cancer stem cells.
Yang YS; Jia XZ; Lu QY; Cai SL; Huang XT; Yang SH; Wood C; Wang YH; Zhou JJ; Chen YD; Yang JS; Yang WJ
Oncogene; 2022 Apr; 41(18):2624-2637. PubMed ID: 35351996
[TBL] [Abstract][Full Text] [Related]
9. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
10. The nuclear DEK interactome supports multi-functionality.
Smith EA; Krumpelbeck EF; Jegga AG; Prell M; Matrka MM; Kappes F; Greis KD; Ali AM; Meetei AR; Wells SI
Proteins; 2018 Jan; 86(1):88-97. PubMed ID: 29082557
[TBL] [Abstract][Full Text] [Related]
11. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
12. The PML-associated protein DEK regulates the balance of H3.3 loading on chromatin and is important for telomere integrity.
Ivanauskiene K; Delbarre E; McGhie JD; Küntziger T; Wong LH; Collas P
Genome Res; 2014 Oct; 24(10):1584-94. PubMed ID: 25049225
[TBL] [Abstract][Full Text] [Related]
13. From ecology to oncology: To understand cancer stem cell dormancy, ask a Brine shrimp (Artemia).
Wood CR; Wu WT; Yang YS; Yang JS; Xi Y; Yang WJ
Adv Cancer Res; 2023; 158():199-231. PubMed ID: 36990533
[TBL] [Abstract][Full Text] [Related]
14. Intercellular trafficking of the nuclear oncoprotein DEK.
Saha AK; Kappes F; Mundade A; Deutzmann A; Rosmarin DM; Legendre M; Chatain N; Al-Obaidi Z; Adams BS; Ploegh HL; Ferrando-May E; Mor-Vaknin N; Markovitz DM
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6847-52. PubMed ID: 23569252
[TBL] [Abstract][Full Text] [Related]
15. Control of tumorigenesis and chemoresistance by the DEK oncogene.
Riveiro-Falkenbach E; Soengas MS
Clin Cancer Res; 2010 Jun; 16(11):2932-8. PubMed ID: 20501624
[TBL] [Abstract][Full Text] [Related]
16. DEK over-expression promotes mitotic defects and micronucleus formation.
Matrka MC; Hennigan RF; Kappes F; DeLay ML; Lambert PF; Aronow BJ; Wells SI
Cell Cycle; 2015; 14(24):3939-53. PubMed ID: 25945971
[TBL] [Abstract][Full Text] [Related]
17. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
18. p300/CBP-associated factor drives DEK into interchromatin granule clusters.
Cleary J; Sitwala KV; Khodadoust MS; Kwok RP; Mor-Vaknin N; Cebrat M; Cole PA; Markovitz DM
J Biol Chem; 2005 Sep; 280(36):31760-7. PubMed ID: 15987677
[TBL] [Abstract][Full Text] [Related]
19. Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.
Capitano ML; Mor-Vaknin N; Saha AK; Cooper S; Legendre M; Guo H; Contreras-Galindo R; Kappes F; Sartor MA; Lee CT; Huang X; Markovitz DM; Broxmeyer HE
J Clin Invest; 2019 May; 129(6):2555-2570. PubMed ID: 31107242
[TBL] [Abstract][Full Text] [Related]
20. DEK is required for homologous recombination repair of DNA breaks.
Smith EA; Gole B; Willis NA; Soria R; Starnes LM; Krumpelbeck EF; Jegga AG; Ali AM; Guo H; Meetei AR; Andreassen PR; Kappes F; Vinnedge LM; Daniel JA; Scully R; Wiesmüller L; Wells SI
Sci Rep; 2017 Mar; 7():44662. PubMed ID: 28317934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
